- Home
- PRAX vs REPX Comparison
PRAX vs REPX Comparison
Compare PRAX & REPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- REPX
- Stock Information
- Founded
- PRAX 2015
- REPX 2016
- Country
- PRAX United States
- REPX United States
- Employees
- PRAX N/A
- REPX N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- REPX Oil & Gas Production
- Sector
- PRAX Health Care
- REPX Energy
- Exchange
- PRAX Nasdaq
- REPX Nasdaq
- Market Cap
- PRAX 599.7M
- REPX 574.1M
- IPO Year
- PRAX 2020
- REPX N/A
- Fundamental
- Price
- PRAX $42.34
- REPX $27.88
- Analyst Decision
- PRAX Strong Buy
- REPX Strong Buy
- Analyst Count
- PRAX 11
- REPX 1
- Target Price
- PRAX $114.73
- REPX $47.00
- AVG Volume (30 Days)
- PRAX 279.7K
- REPX 96.1K
- Earning Date
- PRAX 08-12-2025
- REPX 08-06-2025
- Dividend Yield
- PRAX N/A
- REPX 5.48%
- EPS Growth
- PRAX N/A
- REPX N/A
- EPS
- PRAX N/A
- REPX 4.67
- Revenue
- PRAX $8,122,000.00
- REPX $412,894,000.00
- Revenue This Year
- PRAX N/A
- REPX $2.85
- Revenue Next Year
- PRAX $6,358.50
- REPX $4.05
- P/E Ratio
- PRAX N/A
- REPX $5.94
- Revenue Growth
- PRAX 270.02
- REPX 1.25
- 52 Week Low
- PRAX $26.70
- REPX $21.98
- 52 Week High
- PRAX $91.83
- REPX $37.55
- Technical
- Relative Strength Index (RSI)
- PRAX 54.36
- REPX 55.00
- Support Level
- PRAX $41.64
- REPX $27.67
- Resistance Level
- PRAX $44.99
- REPX $28.94
- Average True Range (ATR)
- PRAX 2.55
- REPX 0.99
- MACD
- PRAX -0.11
- REPX 0.09
- Stochastic Oscillator
- PRAX 51.07
- REPX 63.64
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About REPX Riley Exploration Permian Inc.
Riley Exploration Permian Inc is engaged in the business of exploration for and production of oil and natural gas. The company operations are in Kansas Properties and Tennessee Properties, among others.